Annual EBIT
-$196.70 M
+$144.04 M+42.27%
December 31, 2023
Summary
- As of February 7, 2025, DNLI annual earnings before interest & taxes is -$196.70 million, with the most recent change of +$144.04 million (+42.27%) on December 31, 2023.
- During the last 3 years, DNLI annual EBIT has fallen by -$259.42 million (-413.62%).
- DNLI annual EBIT is now -413.62% below its all-time high of $62.72 million, reached on December 31, 2020.
Performance
DNLI EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$123.19 M
-$6.59 M-5.66%
September 30, 2024
Summary
- As of February 7, 2025, DNLI quarterly earnings before interest & taxes is -$123.19 million, with the most recent change of -$6.59 million (-5.66%) on September 30, 2024.
- Over the past year, DNLI quarterly EBIT has dropped by -$6.59 million (-5.66%).
- DNLI quarterly EBIT is now -150.47% below its all-time high of $244.08 million, reached on December 31, 2020.
Performance
DNLI Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$504.60 M
-$9.39 M-1.90%
September 30, 2024
Summary
- As of February 7, 2025, DNLI TTM earnings before interest & taxes is -$504.60 million, with the most recent change of -$9.39 million (-1.90%) on September 30, 2024.
- Over the past year, DNLI TTM EBIT has dropped by -$9.39 million (-1.90%).
- DNLI TTM EBIT is now -904.56% below its all-time high of $62.72 million, reached on December 31, 2020.
Performance
DNLI TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
DNLI EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +42.3% | -5.7% | -1.9% |
| 3 y3 years | -413.6% | -16.9% | -48.1% |
| 5 y5 years | -324.2% | -16.9% | -48.1% |
DNLI EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +42.3% | -172.3% | +7.1% | -209.3% | at low |
| 5 y | 5-year | -413.6% | +42.3% | -150.5% | +7.1% | -904.6% | at low |
| alltime | all time | -413.6% | +42.3% | -150.5% | +7.1% | -904.6% | at low |
Denali Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$123.19 M(+5.7%) | -$504.60 M(+1.9%) |
| Jun 2024 | - | -$116.59 M(-11.8%) | -$495.21 M(+137.9%) |
| Mar 2024 | - | -$132.25 M(-0.2%) | -$208.14 M(+5.8%) |
| Dec 2023 | -$196.70 M(-42.3%) | -$132.57 M(+16.5%) | -$196.70 M(+16.1%) |
| Sep 2023 | - | -$113.80 M(-166.7%) | -$169.47 M(+3.9%) |
| Jun 2023 | - | $170.48 M(-241.1%) | -$163.16 M(-58.7%) |
| Mar 2023 | - | -$120.81 M(+14.7%) | -$395.06 M(+15.9%) |
| Dec 2022 | -$340.74 M(+15.2%) | -$105.34 M(-2.0%) | -$340.74 M(+9.0%) |
| Sep 2022 | - | -$107.49 M(+75.0%) | -$312.52 M(+7.5%) |
| Jun 2022 | - | -$61.42 M(-7.6%) | -$290.63 M(-0.1%) |
| Mar 2022 | - | -$66.50 M(-13.8%) | -$291.03 M(-1.6%) |
| Dec 2021 | -$295.75 M(-571.6%) | -$77.12 M(-9.9%) | -$295.75 M(-1262.2%) |
| Sep 2021 | - | -$85.59 M(+38.5%) | $25.45 M(-50.0%) |
| Jun 2021 | - | -$61.82 M(-13.2%) | $50.92 M(-1.0%) |
| Mar 2021 | - | -$71.22 M(-129.2%) | $51.47 M(-17.9%) |
| Dec 2020 | $62.72 M | $244.08 M(-506.0%) | $62.72 M(-126.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$60.12 M(-1.9%) | -$239.12 M(+4.3%) |
| Jun 2020 | - | -$61.28 M(+2.2%) | -$229.16 M(-0.6%) |
| Mar 2020 | - | -$59.97 M(+3.8%) | -$230.64 M(+8.2%) |
| Dec 2019 | -$213.18 M(+359.7%) | -$57.76 M(+15.2%) | -$213.18 M(+164.2%) |
| Sep 2019 | - | -$50.16 M(-20.1%) | -$80.70 M(+17.8%) |
| Jun 2019 | - | -$62.76 M(+47.6%) | -$68.51 M(+8.5%) |
| Mar 2019 | - | -$42.51 M(-156.9%) | -$63.13 M(+36.1%) |
| Dec 2018 | -$46.37 M(-48.6%) | $74.72 M(-296.8%) | -$46.37 M(-67.9%) |
| Sep 2018 | - | -$37.96 M(-33.8%) | -$144.63 M(+12.2%) |
| Jun 2018 | - | -$57.38 M(+122.9%) | -$128.96 M(+37.0%) |
| Mar 2018 | - | -$25.75 M(+9.4%) | -$94.14 M(+4.4%) |
| Dec 2017 | -$90.14 M(+3.1%) | -$23.54 M(+5.6%) | -$90.14 M(+4.4%) |
| Sep 2017 | - | -$22.29 M(-1.2%) | -$86.38 M(+34.8%) |
| Jun 2017 | - | -$22.57 M(+3.8%) | -$64.09 M(+54.4%) |
| Mar 2017 | - | -$21.74 M(+10.0%) | -$41.52 M(+110.0%) |
| Dec 2016 | -$87.43 M(+424.2%) | -$19.78 M | -$19.78 M |
| Dec 2015 | -$16.68 M | - | - |
FAQ
- What is Denali Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Denali Therapeutics?
- What is Denali Therapeutics annual EBIT year-on-year change?
- What is Denali Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Denali Therapeutics?
- What is Denali Therapeutics quarterly EBIT year-on-year change?
- What is Denali Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Denali Therapeutics?
- What is Denali Therapeutics TTM EBIT year-on-year change?
What is Denali Therapeutics annual earnings before interest & taxes?
The current annual EBIT of DNLI is -$196.70 M
What is the all time high annual EBIT for Denali Therapeutics?
Denali Therapeutics all-time high annual earnings before interest & taxes is $62.72 M
What is Denali Therapeutics annual EBIT year-on-year change?
Over the past year, DNLI annual earnings before interest & taxes has changed by +$144.04 M (+42.27%)
What is Denali Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of DNLI is -$123.19 M
What is the all time high quarterly EBIT for Denali Therapeutics?
Denali Therapeutics all-time high quarterly earnings before interest & taxes is $244.08 M
What is Denali Therapeutics quarterly EBIT year-on-year change?
Over the past year, DNLI quarterly earnings before interest & taxes has changed by -$6.59 M (-5.66%)
What is Denali Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of DNLI is -$504.60 M
What is the all time high TTM EBIT for Denali Therapeutics?
Denali Therapeutics all-time high TTM earnings before interest & taxes is $62.72 M
What is Denali Therapeutics TTM EBIT year-on-year change?
Over the past year, DNLI TTM earnings before interest & taxes has changed by -$9.39 M (-1.90%)